Inventor · disambiguated record
John Polo
Also filed as: POLO JOHN · POLO JOHN M
27 granted patents·14 pending applications·2,623 citations·filing 1995–2014
98Inventor score
Files withCHIRON CORP18NOVARTIS VACCINES & DIAGNOSTIC11POLO JOHN M3NOVARTIS VACCINES & DIAGNOSTICS INC1O' HAGAN DEREK1
Top patents by PatentIndex Score
41 records- 0199US5814482AEukaryotic layered vector initiation systemsFiled 1996·Granted Sep 29, 1998·536 cites·25 claims
- 0298US6015686AEukaryotic layered vector initiation systemsVIAGENE INC·Filed 1995·Granted Jan 18, 2000·253 cites·20 claims
- 0398US5843723AAlphavirus vector constructsCHIRON CORP·Filed 1996·Granted Dec 1, 1998·327 cites·47 claims
- 0498US5789245AAlphavirus structural protein expression cassettesCHIRON CORP·Filed 1996·Granted Aug 4, 1998·345 cites·29 claims
- 0597US7977091B2Eukaryotic layered vector initiation systemsNOVARTIS VACCINES & DIAGNOSTIC·Filed 2009·Granted Jul 12, 2011·38 cites·4 claims
- 0696US6767699B2Method for the quantitation of alphavirus replicon particlesCHIRON CORP·Filed 2001·Granted Jul 27, 2004·50 cites·5 claims
- 0796US6376236B1Recombinant alphavirus particlesCHIRON CORP·Filed 1999·Granted Apr 23, 2002·121 cites·11 claims
- 0896US6329201B1Compositions and methods for packaging of alphavirus vectorsCHIRON CORP·Filed 2000·Granted Dec 11, 2001·86 cites·10 claims
- 0996US6015694AMethod for stimulating an immune response utilizing recombinant alphavirus particlesCHIRON CORP·Filed 1997·Granted Jan 18, 2000·228 cites·11 claims
- 1094US7811812B2Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesisNOVARTIS VACCINES & DIAGNOSTIC·Filed 2003·Granted Oct 12, 2010·43 cites·16 claims
- 1194US7771979B2Compositions and methods for generating an immune response utilizing alphavirus-based vector systemsNOVARTIS VACCINES & DIAGNOSTIC·Filed 2007·Granted Aug 10, 2010·39 cites·21 claims
- 1293US7572453B2Chimeric alphavirus replicon particlesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2006·Granted Aug 11, 2009·18 cites·23 claims
- 1393US6342372B1Eukaryotic layered vector initiation systems for production of recombinant proteinsCHIRON CORP·Filed 1999·Granted Jan 29, 2002·90 cites·14 claims
- 1492US8647864B2Compositions and methods for generating an immune response utilizing alphavirus-based vector systemsPOLO JOHN M·Filed 2010·Granted Feb 11, 2014·18 cites·21 claims
- 1592US7744900B2Enhancement of the immune response for vaccine and gene therapy applicationsNOVARTIS VACCINES & DIAGNOSTIC·Filed 2008·Granted Jun 29, 2010·20 cites·15 claims
- 1691US9255126B2Chimeric alphavirus replicon particlesPOLO JOHN M·Filed 2009·Granted Feb 9, 2016·20 cites·20 claims
- 1790US6391632B1Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesisCHIRON CORP·Filed 1999·Granted May 21, 2002·63 cites·28 claims
- 1889US6426196B1Alphavirus structural protein expression cassettesCHIRON CORP·Filed 1999·Granted Jul 30, 2002·57 cites·27 claims
- 1989US6242259B1Compositions and methods for packing of alphavirus vectorsCHIRON CORP·Filed 1999·Granted Jun 5, 2001·85 cites·72 claims
- 2088US8158418B2Chimeric alphavirus replicon particlesPOLO JOHN·Filed 2009·Granted Apr 17, 2012·13 cites·11 claims
- 2188US7572628B2Eukaryotic layered vector initiation systemsNOVARTIS VACCINES & DIAGNOSTIC·Filed 2003·Granted Aug 11, 2009·9 cites·34 claims
- 2288US7531180B2Chimeric alphavirus replicon particlesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2002·Granted May 12, 2009·15 cites·55 claims
- 2386US6451592B1Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesisCHIRON CORP·Filed 1997·Granted Sep 17, 2002·50 cites·26 claims
- 2484US9730997B2Alphavirus vectors for respiratory pathogen vaccinesNOVARTIS VACCINES & DIAGNOSTICS INC·Filed 2014·Granted Aug 15, 2017·9 cites·16 claims
- 2581US9024001B2Alphavirus replicon packaging constructsTANG ZEQUN·Filed 2005·Granted May 5, 2015·8 cites·20 claims
- 2679US6465634B1Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesisCHIRON CORP·Filed 1999·Granted Oct 15, 2002·45 cites·25 claims
- 2773US6458560B1Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesisCHIRON CORP·Filed 1999·Granted Oct 1, 2002·37 cites·24 claims
- 2867US2010055128A1Method for the purification of alphavirus replicon particlesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2008·Application pending·0 cites
- 2964US2008026071A1Microparticles for delivery of heterologous nucleic acidsO'HAGAN DEREK·Filed 2007·Application pending·0 cites
- 3064US2005112752A1Method for the purification of alphavirus replicon particlesCHIRON CORP·Filed 2004·Application pending·0 cites
- 3161US2004029278A1Eukaryotic layered vector initiation systemsCHIRON CORP·Filed 2002·Application pending·0 cites
- 3260US2010330121A1Recombinant alphavirus-based vectors with reduced inhibition of cellular macro-molecular synthesisNOVARTIS VACCINES & DIAGNOSTIC·Filed 2010·Application pending·0 cites
- 3359US2012231526A1Method for the Purification of Alphavirus Replicon ParticlesPOLO JOHN M·Filed 2012·Application pending·0 cites
- 3457US2003232324A1Chimeric alphavirus replicon particlesCHIRON CORP·Filed 2002·Application pending·0 cites
- 3553US2006257852A1Severe acute respiratory syndrome coronavirusCHIRON CORP·Filed 2004·Application pending·0 cites
- 3650US2009104226A1Alphavirus Vectors for Respiratory Pathogen VaccinesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2005·Application pending·0 cites
- 3747US2003021766A1Nucleic acid mucosal immunizationFiled 2002·Application pending·0 cites
- 3846US2003138453A1Microparticles for delivery of heterologous nucleic acidsFiled 2001·Application pending·0 cites
- 3946US2012114693A1Nucleic acid mucosal immunizationVAJDY MICHAEL·Filed 2012·Application pending·0 cites
- 4045US2011002958A1Alphavirus Vectors for Respiratory Pathogen VaccinesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2010·Application pending·0 cites
- 4144US2003170871A1Alphavirus-based vectors for persistent infectionCHIRON CORP·Filed 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →